title: Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution.
abstract: Thirty patients with haematological malignancies received peripheral blood stem cells from human leucocyte antigen (HLA)-identical sibling donors after non-myeloablative conditioning with fludarabine and total body irradiation. Twenty-seven patients received the transplant as an outpatient procedure. All patients engrafted. The probability of acute graft-versus-host disease (GVHD) grades II-IV and extensive chronic GVHD was 57% and 80%, respectively. Patients alive on day +365 experienced a median of 44 d (range 4-151) of hospitalization during the first year. In the entire cohort, GVHD accounted for 22%, infections for 18%, thrombotic thrombocytopenic purpura (TTP) for 16% and engraftment syndrome for 14% of the time in hospital. The 1-year risk of TTP was 26%. Acute GVHD was a risk factor for the development of TTP (P = 0.008). With a median follow-up of 602 d, the 2-year estimates for overall survival, progression-free survival, non-relapse mortality and relapse related mortality were 68%, 43%, 22% and 13%, respectively. This transplantation regimen is feasible and induces long-term remissions in heavily pretreated patients. The procedure can be performed in the outpatient setting, but complications could result in a substantial number of admissions during the first year.
authors.affiliation: The Lymphocyte Research Laboratory, Department of Haematology L 4041, Rigshospitalet, Blegdamsvej 8, DK-2100 Copenhagen, Denmark. slykkep@rh.dk
authors.forename: Søren L
authors.initials: SL
authors.lastname: Petersen
authors.forename: Hans O
authors.initials: HO
authors.lastname: Madsen
authors.forename: Lars P
authors.initials: LP
authors.lastname: Ryder
authors.forename: Arne
authors.initials: A
authors.lastname: Svejgaard
authors.forename: Bodil K
authors.initials: BK
authors.lastname: Jakobsen
authors.forename: Henrik
authors.initials: H
authors.lastname: Sengeløv
authors.forename: Carsten
authors.initials: C
authors.lastname: Heilmann
authors.forename: Ebbe
authors.initials: E
authors.lastname: Dickmeiss
authors.forename: Lars L
authors.initials: LL
authors.lastname: Vindeløv
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D011697:Purpura, Thrombotic Thrombocytopenic / Q000209:etiology; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome